Navigation Links
Weekly dose of osteoporosis drug prevents bone loss after breast cancer treatment
Date:9/18/2007

HONOLULU, Sept. 18 Breast cancer survivors who took a weekly dose of risedronate, sold as Actonel, lost significantly less bone than those who did not take the drug, according to a two-year study from the University of Pittsburgh School of Medicine presented this week at the 29th annual meeting of the American Society for Bone and Mineral Research. Scientific sessions continue through Wednesday at the Hawaii Convention Center.

Susan Greenspan, M.D., director of the Osteoporosis Prevention and Treatment Center and Bone Health program at the University of Pittsburgh Medical Center, and colleagues evaluated 87 women, mean age 50, enrolled in the Prevention of Osteoporosis in Postmenopausal Women with Breast Cancer Following Chemotherapy study. All participants in the randomized, double-blind trial received calcium and vitamin D supplements. However, half took 35 milligrams of risedronate once a week while others took a placebo.

Chemotherapy drugs and other medical treatments for breast cancer are known to induce menopause, which can kick-start bone loss, putting survivors at risk for osteoporotic fractures, said Dr. Greenspan, an internationally respected osteoporosis researcher and professor of medicine at Pitt. This study also looked at changes in spine and hip bone mineral density, as well as evidence of bone breakdown.

Ninety-seven percent of study participants had normal or low bone mass at enrollment. At baseline, many were taking tamoxifen, a breast cancer drug aimed at estrogen-sensitive tumors that also is sometimes used as a preventive therapy by women at high risk for breast cancer.

While tamoxifen can have a positive impact on bone in postmenopausal women, a small percentage of women were taking aromatase inhibitors (also used for prevention), which can have a negative effect on bone. During the second year of the study, about half the women began taking aromatase inhibitors and stopped taking tamoxifen.

After 24 months, women in the placebo group had significant bone loss in the spine and hip that we didnt see in women taking risedronate, noted Dr. Greenspan. In fact, women taking risedronate had a bone density much higher in the spine and hip than women in the placebo group. The researchers also observed that the greatest bone loss was found in women on aromatase inhibitors. Even so, risedronate continued to be successful in preventing bone loss.

We conclude that once weekly doses of risedronate improves bone density and prevents excess bone loss in breast cancer survivors, the researchers noted.


'/>"/>

Contact: Michele Baum
BaumMD@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. First head-to-head trials of once weekly Fosamax and Actonel therapies
2. Yale Cancer Center Answers: A New Weekly Radio Progam on WNPR
3. New treatment for Osteoporosis
4. Osteoporosis in men
5. Patients With Severe Hemophilia At Risk Of Developing Osteoporosis
6. Osteoporosis Drugs: right time to take-off
7. Fluoride Found Effective in Osteoporosis
8. Cement injections linked to osteoporosis
9. Cure for osteoporosis in prostate cancer patients
10. Mutation connected to Osteoporosis
11. Osteoporosis associated with Childhood Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Horizon Blue Cross Blue Shield ... hospitals to make transformative changes in how health care is delivered and financed ... in discussing breakthroughs in cellular medicine to treat disease. After accepting an invitation ...
(Date:4/28/2016)... ... April 28, 2016 , ... One way to ignore solid evidence ... unfortunately true. But we toss the baby out with the bathwater when we ignore ... for identifying higher-quality studies and otherwise making better use of education policy research. , ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... leader in Aesthetic Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge ... Nationwide Plastic Surgery Collaborative Residency Network. The platform is scheduled to launch in ...
(Date:4/28/2016)... ... April 28, 2016 , ... A first-time look at workers’ compensation claims in ... Workers Compensation Research Institute (WCRI) announced, and that costs per claim were ... Kentucky, 16th Edition , found that indemnity costs per claim and benefit delivery expenses ...
(Date:4/28/2016)... ... April 28, 2016 , ... Metabolic Nutrition today announced ... week’s 2016 Europa Games Get Fit and Sports Expo in Orlando, Florida. ... Orlando Expo coming up April 29-30, was selected as the perfect event to introduce ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , April 27, 2016 Transparency ... "Skincare Devices Market - Global Industry Analysis, Size, Share, ... the report, the global skincare devices market was valued ... to expand at a CAGR of 10.1% from 2015 ... Browse the full Skincare Devices Market (Treatment Device ...
(Date:4/27/2016)... Kan. , April 27, 2016  Bayer ... , a senior from the University of Florida ... of the Bayer Excellence in Communication Award (BECA). ... schools, which were awarded a total of $70,000 ... the last four years, Bayer has provided a ...
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
Breaking Medicine Technology: